Literature DB >> 28007411

A qualitative analysis of prescribers' and dispensers' views on improving prescription drug monitoring programs.

Neal A Carnes1, Eric R Wright2, Connor W Norwood3.   

Abstract

BACKGROUND: Prescription drug abuse is epidemic in the United States (US). To help address the problem, most states operate prescription drug monitoring programs (PDMPs). PDMPs are designed to monitor and help control the distribution of controlled therapeutic medications and to assist prescribers and dispensers in making informed clinical decisions. To this end, PDMPs rely on timely and accurate data submission, as well as review of the data. Consequently, provider acceptance of these systems is essential to maximize their effectiveness.
OBJECTIVES: This article explores licensed prescribers' and dispensers' opinions regarding prescription drug monitoring.
METHODS: The study surveyed licensed prescribers and dispensers about their experiences and views on drug monitoring, prescribing and dispensing practices, and on prescription drug abuse in general. Two open-ended questions were posed as part of a larger, end-user survey. The analysis culled thematically-coded excerpts to these two questions.
RESULTS: Respondents offered a range of comments that unearthed important disagreements among prescribers and dispensers over the administration and ethics pertaining to PDMPs. At the same time, some respondents suggested means to enhance PDMPs functionality.
CONCLUSION: Attending to and rectifying providers' views, while considering their improvement suggestions may boost PDMPs effectiveness by maximizing buy-in and utilization. The potential speaks to advancing a tool that intends to help address alarming rates of prescription drug abuse.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Dispensers; Ethics; Health policy; Prescribers; Prescription drug monitoring programs

Mesh:

Year:  2016        PMID: 28007411     DOI: 10.1016/j.sapharm.2016.12.002

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  5 in total

Review 1.  Provider perceptions of system-level opioid prescribing and addiction treatment policies.

Authors:  Rebecca L Haffajee; Cecelia A French
Journal:  Curr Opin Psychol       Date:  2019-02-04

2.  Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.

Authors:  Thomas R Radomski; Felicia R Bixler; Susan L Zickmund; KatieLynn M Roman; Carolyn T Thorpe; Jennifer A Hale; Florentina E Sileanu; Leslie R M Hausmann; Joshua M Thorpe; Katie J Suda; Kevin T Stroupe; Adam J Gordon; Chester B Good; Michael J Fine; Walid F Gellad
Journal:  J Gen Intern Med       Date:  2018-03-08       Impact factor: 5.128

3.  Exploring perspectives on changing opioid prescribing practices: A qualitative study of community stakeholders in the HEALing Communities Study.

Authors:  Daniel M Walker; Janet E Childerhose; Sadie Chen; Nicolette Coovert; Rebecca D Jackson; Natasha Kurien; Ann Scheck McAlearney; Jaclyn Volney; Daniel P Alford; Julie Bosak; Douglas R Oyler; Laura K Stinson; Melika Behrooz; Mia-Cara Christopher; Mari-Lynn Drainoni
Journal:  Drug Alcohol Depend       Date:  2022-02-02       Impact factor: 4.492

4.  Prescribing for Patients Seeking Maternal and Child Healthcare in Sierra Leone: A Multiregional Retrospective Cross-Sectional Assessments of Prescribing Pattern Using WHO Drug Use Indicators.

Authors:  John Alimamy Kabba; Peter Bai James; Zongjie Li; Christian Hanson; Jie Chang; Chenai Kitchen; Minghuan Jiang; Mingyue Zhao; Caijun Yang; Yu Fang
Journal:  Risk Manag Healthc Policy       Date:  2020-11-10

5.  Health Care Provider Utilization of Prescription Monitoring Programs: A Systematic Review and Meta-Analysis.

Authors:  Alysia Robinson; Maria N Wilson; Jill A Hayden; Emily Rhodes; Samuel Campbell; Peter MacDougall; Mark Asbridge
Journal:  Pain Med       Date:  2021-07-25       Impact factor: 3.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.